Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07940369 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1, PF-07940369 or Placebo | EXPERIMENTAL | Multiple oral dosing |
| Cohort 2, PF-07940369 or Placebo | EXPERIMENTAL | Multiple oral dosing |
| Cohort 3, PF-07940369 or Placebo | EXPERIMENTAL | Multiple oral dosing |
| PF-07940369 and Placebo (Cohort 1) | EXPERIMENTAL | Single dose administration of PF-07940369 and placebo; Within a cohort, participants will receive up to 4 oral doses of PF-07940369 and up to 2 doses of placebo. |
| PF-07940369 and Placebo (Cohort 2) | PLACEBO_COMPARATOR | Single dose administration of PF-07940369 and placebo; Within a cohort, participants will receive up to 4 oral doses of PF-07940369 and up to 2 doses of placebo. |
| Name | Type | Description |
|---|---|---|
| PF-07940369 | DRUG | Oral Tablets |
| Placebo | DRUG | Oral Tablets |
Inclusion Criteria: * Male participants and female participants who are not of childbearing potential who are overtly healthy as determine by medical evaluation including medical history, physical examination, laboratory tests, and standard 12 lead electrocardiogram (ECG). * Body mass index (BMI) o...
PF-07940369 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It is in Phase 1 clinical development, and the specific disease or condition it is intended to treat has not been disclosed. Two Phase 1 trials in healthy adult volunteers have been completed.
PF-07940369 is being developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored both of the completed Phase 1 studies of the compound, which were conducted in Belgium.
PF-07940369 is in Phase 1 clinical development. Two Phase 1 trials have been completed, and no active trials are currently listed. The compound is investigational and has not been approved by the FDA for any indication.
PF-07940369 has been studied in two completed Phase 1 trials: NCT07514156, which enrolled 30 healthy adults, and NCT06532383, which enrolled 22 healthy adults. Both were conducted in Belgium and together enrolled 52 participants.
Both PF-07940369 Phase 1 trials were randomized, double-blind, and placebo-controlled studies in healthy adult volunteers aged 18 and older. NCT07514156 enrolled 30 participants and NCT06532383 enrolled 22, for a combined total of 52 participants across the two completed studies.